Effect of Sulforaphane-rich Broccoli Sprout Homogenate on Ozone Induced Inflammation Through Modulation of NRF2
NCT ID: NCT01625130
Last Updated: 2015-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2013-10-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation
NCT01315665
Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers
NCT01269723
Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers
NCT01129466
Broccoli Sprout Extract in Preventing Lung Cancer in Smokers
NCT00255775
Effects of Sulforaphane on Normal Prostate Tissue
NCT00946309
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Qualified volunteers will next be seen for a training visit at which time they will undergo physical exam by a study physician. After baseline spirometry is evaluated, the subject will exercise on a treadmill, and measurements of minute ventilation will be collected. Treadmill speed and/or elevation will be adjusted until the subject's minute ventilation is at the target level of 30-40 L/min. The resulting speed and elevation will be used during the ozone exposure sessions. At the training visit, participants will also undergo nasal epithelial biopsy from one nare, and a buccal swab will be collected for genotyping. Baseline blood samples will also be collected at this time for analyses of markers of inflammation, cytokine assessments, SFN levels and complete blood cell count with differential.
After completion of the training session, the subject will return for 4 sequential days. During the first 3 days, subjects will ingest (observed ingestion) either broccoli sprout homogenate or alfalfa sprout homogenate based on earlier randomization. One hour after the supplement dose on the 3rd day, the volunteer will undergo exposure to 0.4 ppm ozone for a 2 hour period. During exposure, subjects will perform 15 minutes of moderate exercise on a treadmill (minute ventilation = 30-40 L/min), each separated by 15 minutes of seated rest. Heart rate and rhythm will be continuously monitored throughout the exposure. Spirometry and symptom scoring will be performed both prior to and after exposure. One hour after the end of exposure, a nasal epithelial biopsy will be collected from the nare that is contralateral to that used at the prior visit. Four hours after completion of the exposure, blood will be drawn for study endpoints and a sputum induction will be performed. The following day the subject will return for a follow-up visit to include vital signs, symptom scoring, spirometry, sputum induction and venipuncture for blood endpoints.
Subjects will be required to abstain from a list of vegetables for 1 week prior to each study session until the completion of that session. Subjects will also be asked to maintain a food diary for the same time.
After a 2 to 6 weeks washout period, participants will again return for a repeated sequence of 4 days with 3 days of supplement ingestion followed by ozone exposure using the alternate supplement and a 24 hour post exposure follow-up visit. Samples for analyses will be collected at the same time points as those used in the initial sequence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
broccoli sprout homogenate (BSH)
Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
Broccoli sprout homogenate
Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
alfalfa sprout homogenate
Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
alfalfa sprout homogenate
200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Broccoli sprout homogenate
Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
alfalfa sprout homogenate
200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
FVC of \> 80 % of that predicted for gender, ethnicity, age and height; FEV1 of \> 80 % of that predicted for gender, ethnicity, age and height; FEV1/FVC ratio of \> .70.
2. Negative pregnancy test for females who are not s/p hysterectomy with oophorectomy;
3. Willing to avoid corticosteroids and non-steroidal anti-inflammatory medications for 1 week prior the baseline screening visit and again for 1 week prior to all remaining visits;
4. Willing to avoid antioxidant vitamins and cruciferous vegetables as well as juices/drinks with added vitamin supplements for 7 days prior the baseline screening visit and throughout initial dosing period and ozone challenge as well as 7 days prior to the start of the 2nd dosing period and subsequent challenge.
\-
Exclusion Criteria
2. Use of tricyclics and MAO inhibitors;
3. Pregnancy or nursing a baby;
4. Any current smoking;
5. Viral upper respiratory tract infection within 2 weeks of challenge;
6. Any acute infection requiring antibiotics within 2 weeks of challenge;
7. Abnormal physical findings at the baseline visit:
Abnormalities on lung auscultation Temperature \> 37.8 Systolic BP\>150 mm hg or \< 85 mm Hg or diastolic BP\>90 mm Hg or \< 50 Oxygen saturation of \< 94%;
8. Subjects must demonstrate the ability to produce an acceptable induced sputum sample during the screening session. If the sample is unsatisfactory, the subject's participation will end at that point;
9. Subjects who have been prescribed daily anti-inflammatory medications or medications for asthma will be excluded. Oral contraceptives are acceptable. Antidepressants and other medications may be permitted if in the opinion of the investigator the medication will not interfere with the study procedures or compromise safety; and if the dosage has been stable for 1 month;
10. Subjects who are unwilling to refrain from strenuous physical activity for 24 hours before and after exposure;
11. Current nutritional disorder such as anorexia, bulimia, irritable bowel syndrome, Crohn's disease etc;
12. Current use of immunosuppressive drugs;
13. History of intolerance of or aversion to broccoli;
14. Inability or unwillingness of a participant to give written informed consent;
15. Receipt of LAIV (Live Attenuated Influenza Vaccine), also known as FluMist®, or other live vaccine within the prior 14 days.
16. Orthopedic injuries or impediments that would preclude treadmill exercise.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Environmental Protection Agency (EPA)
FED
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michelle Hernandez, MD
Assistant Professor of Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michelle Hernandez
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UNC Center for Environmental Medicine, Asthma and Lung Biology
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Duran CG, Burbank AJ, Mills KH, Duckworth HR, Aleman MM, Kesic MJ, Peden DB, Pan Y, Zhou H, Hernandez ML. A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation. Respir Res. 2016 Jul 22;17(1):89. doi: 10.1186/s12931-016-0406-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-1296
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.